Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

57.12USD
1:34am IST
Change (% chg)

$-0.40 (-0.70%)
Prev Close
$57.52
Open
$56.78
Day's High
$57.22
Day's Low
$56.46
Volume
256,873
Avg. Vol
282,763
52-wk High
$57.70
52-wk Low
$41.73

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.91
Market Cap(Mil.): $118,597.70
Shares Outstanding(Mil.): 2,062.56
Dividend: 0.76
Yield (%): 1.32

Financials

  NVO.N Industry Sector
P/E (TTM): 34.49 35.92 38.01
EPS (TTM): 1.67 -- --
ROI: 82.69 16.11 15.44
ROE: 91.03 16.90 16.48
Search Stocks

BRIEF-Novo Nordisk says 3-year Saxenda treatment reduced diabetes risk

* Treatment with obesity drug Saxenda for three years reduced risk of developing type 2 diabetes compared with placebo

22 May 2015

Novo Nordisk, Baxter clash over hemophilia drug patent

COPENHAGEN - Novo Nordisk on Wednesday rejected claims by Baxter International that its drug used substances developed by the U.S. rival, following the launch this week of a U.S. investigation into possible patent infringement.

20 May 2015

UPDATE 1-Novo Nordisk, Baxter clash over haemophilia drug patent

COPENHAGEN, May 20 - Novo Nordisk on Wednesday rejected claims by Baxter International that its drug used substances developed by the U.S. rival, following the launch this week of a U.S. investigation into possible patent infringement.

20 May 2015

Novo Nordisk rejects Baxter patent claim over Novoeight

COPENHAGEN, May 20 - Novo Nordisk said on Wednesday it rejected claims by U.S. rival Baxter International that it had infringed patents on drugs to treat the bleeding disorder haemophilia, the Danish company said on Wednesday.

20 May 2015

BRIEF-Novo Nordisk sells auto-immune licence to J&J unit

* Says Janssen Biotech Inc will acquire licence to further develop and commercialise a clinical programme focused on therapy within auto-immune diseases

20 May 2015

Novo Nordisk weighs diabetes drug's use in fatty liver disease

COPENHAGEN - Novo Nordisk is looking into recent clinical trial data that show its diabetes drug Victoza has potential as a treatment for fatty liver disease, a hot area for pharmaceutical development.

18 May 2015

REFILE-Novo Nordisk weighs diabetes drug's use in fatty liver disease

COPENHAGEN, May 18 - Novo Nordisk is looking into recent clinical trial data that show its diabetes drug Victoza has potential as a treatment for fatty liver disease, a hot area for pharmaceutical development.

18 May 2015

Former Novo Nordisk IT unit reports jump in profit after IPO

COPENHAGEN, May 12 - IT services business NNIT , a unit of drugmaker Novo Nordisk until its March listing, reported a rise in operating profit in its first earnings report as a publicly listed company on the Copenhagen stock exchange.

12 May 2015

BRIEF-Novo Nordisk says Saxenda provides benefits beyond weight loss

* Says new data demonstrated Saxenda provides benefits beyond weight loss

08 May 2015

UPDATE 1-Denmark's Lundbeck lands Novo Nordisk heavyweight as CEO

COPENHAGEN, May 6 - Drugmaker Lundbeck named Kaare Schultz as its new chief a week after the respected executive quit Novo Nordisk, a coup for the struggling smaller firm that sent its shares up 25 percent.

06 May 2015

Competitors

  Price Chg
Sanofi SA (SASY.PA) €92.27 --
Eli Lilly and Co (LLY.N) $76.41 +1.51

Earnings vs. Estimates

Search Stocks